Trial Profile
A Phase I Study of Talazoparib (BMN 673) Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Talazoparib (Primary) ; Filgrastim; Pegfilgrastim; Temozolomide
- Indications Adrenocortical carcinoma; Carcinoma; Chondrosarcoma; Ewing's sarcoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Synovial sarcoma; Wilms' tumour
- Focus Adverse reactions
- 11 Aug 2020 Results published in the European Journal of Cancer
- 16 Apr 2020 Status changed from active, no longer recruiting to completed.
- 07 Nov 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Mar 2020.